BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32319565)

  • 1. miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
    Zhang KJ; Hu Y; Luo N; Li X; Chen FY; Yuan JQ; Guo L
    Int J Oncol; 2020 May; 56(5):1240-1251. PubMed ID: 32319565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
    Chen LL; Zhang ZJ; Yi ZB; Li JJ
    Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-92b inhibited cells EMT by targeting Gabra3 and predicted prognosis of triple negative breast cancer patients.
    Li YY; Zheng XH; Deng AP; Wang Y; Liu J; Zhou Q; Cheng GY; Jiang Q
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10433-10442. PubMed ID: 31841197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CircWHSC1 regulates malignancy and glycolysis by the miR-212-5p/AKT3 pathway in triple-negative breast cancer.
    Ding L; Xie Z
    Exp Mol Pathol; 2021 Dec; 123():104704. PubMed ID: 34624276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA DANCR upregulation induced by TUFT1 promotes malignant progression in triple negative breast cancer via miR-874-3p-SOX2 axis.
    Wu G; Zhou H; Li D; Zhi Y; Liu Y; Li J; Wang F
    Exp Cell Res; 2020 Nov; 396(2):112331. PubMed ID: 33058834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-200c Inhibits the Metastasis of Triple-Negative Breast Cancer by Targeting ZEB2, an Epithelial-Mesenchymal Transition Regulator.
    Chen H; Li Z; Zhang L; Zhang L; Zhang Y; Wang Y; Xu M; Zhong Q
    Ann Clin Lab Sci; 2020 Jul; 50(4):519-527. PubMed ID: 32826250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-137 Suppresses Triple-Negative Breast Cancer Stemness and Tumorigenesis by Perturbing BCL11A-DNMT1 Interaction.
    Chen F; Luo N; Hu Y; Li X; Zhang K
    Cell Physiol Biochem; 2018; 47(5):2147-2158. PubMed ID: 29975921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2.
    Lv ZD; Yang DX; Liu XP; Jin LY; Wang XG; Yang ZC; Liu D; Zhao JJ; Kong B; Li FN; Wang HB
    Cell Physiol Biochem; 2017; 44(5):1785-1795. PubMed ID: 29216628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-6838-5p suppresses cell metastasis and the EMT process in triple-negative breast cancer by targeting WNT3A to inhibit the Wnt pathway.
    Liu G; Wang P; Zhang H
    J Gene Med; 2019 Dec; 21(12):e3129. PubMed ID: 31693779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
    Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
    Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-1246 suppresses the metastasis of breast cancer cells by targeting the DYRK1A/PGRN axis to prevent the epithelial-mesenchymal transition.
    Wang P; Chen W; Zhang Y; Zhong Q; Li Z; Wang Y
    Mol Biol Rep; 2022 Apr; 49(4):2711-2721. PubMed ID: 35059968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer.
    Ji H; Sang M; Liu F; Ai N; Geng C
    Pathol Res Pract; 2019 Apr; 215(4):697-704. PubMed ID: 30611621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miR‑30a inhibits epithelial‑mesenchymal transition and metastasis in triple‑negative breast cancer by targeting ROR1.
    Wang X; Qiu H; Tang R; Song H; Pan H; Feng Z; Chen L
    Oncol Rep; 2018 Jun; 39(6):2635-2643. PubMed ID: 29693179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene.
    Wang YL; Liang RH; Wang CY; Zhang RP; Wu SY; Han X; Zhang GL
    Clin Transl Oncol; 2022 Jan; 24(1):84-92. PubMed ID: 34181232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative breast cancer cells by upregulating TRABD.
    Wu D; Jia H; Zhang Z; Li S
    Bioorg Chem; 2021 Apr; 109():104722. PubMed ID: 33618253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non‑coding RNA TTN‑AS1 regulates the proliferation, invasion and migration of triple‑negative breast cancer by targeting miR‑211‑5p.
    Sun E; Liu X; Lu C; Liu K
    Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
    Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SNHG14 promotes the tumorigenesis and metastasis of colorectal cancer through miR-32-5p/SKIL axis.
    Ye T; Zhang N; Wu W; Yang B; Wang J; Huang W; Tang D
    In Vitro Cell Dev Biol Anim; 2019 Dec; 55(10):812-820. PubMed ID: 31471872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.